SCT520FF

Phase 2Small molecule

SSinocelltech Ltd.

SCT520FF is one of 50 small molecule programs targeting Efficacy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EfficacyRecruiting

EfficacyPhase 2

Recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

5 2

Paraplatin

AAvyxa

Phase 3

4 3

Alimta

SShawn Eagle

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 5

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 6

Veracept

SSebela Women's Health Inc.

Phase 3

1 7

Levocept

SSebela Women's Health Inc.

Phase 3

1 8

Aralen

Sanofi

Preclinical

2 9

Primaquine

Sanofi

Preclinical

2 10

Proamatine

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Efficacy

NCT06672536

Clinical

Trials by Indication[1]

Efficacy1 trial

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

Recruiting·SSinocelltech Ltd.·Phase 1/2·NCT06672536·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SCT520FF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCT520FF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCT520FF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinocelltech Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSinocelltech Ltd.

SCT520FF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Efficacy1 trial

References

Drug Info

Quick Facts

Related News